AdipoPharma is developing a first-in-class drug that reverses insulin resistance. Their lead compound, PATAS, will restore glycemic control in patients with Type 2 diabetes, and has the potential to decrease its associated cardiovascular and renal co-morbidities.
Cellaïon aims to stop the progression of- and rescue - severe chronic liver diseases by controlling inflammation and restoring lost function, thereby, allowing the organ to regenerate. Their lead product, HepaStem®, is currently in the Phase IIb clinical trial for the treatment of Acute on Chronic Liver Failure (ACLF).
Metabolys is developing a small molecule to treat patients suffering from metabolic diseases, especially Non Alcoholic Steato-Hepatitis (NASH). This small molecule (MTBL0036) targets the mitochondrial pyruvate carrier (MPC). Pyruvate lies at a central biochemical node connecting carbohydrate, amino acid, and fatty acid metabolism, and the regulation of pyruvate flux into mitochondria represents a critical step in intermediary metabolism impacting numerous diseases. With the first preclinical data generated by the company, the MTBL0036 seems to be the most efficient of all the orally active anti-NASH and antifibrotic candidates in development when assessed with the STAM animal model of NASH. Easy to produce, it seems to be very efficacious for inhibiting both inflammation and liver cell destruction and could potentially be used complementary of other anti-NASH candidates.
Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.
DIM3 (Disease in management at the 3rd dimension) is a digital healthcare company co-founded in 2012, whose mission is to develop an application to monitor and improve enteral and parenteral nutrition. The company addresses a huge medical need in a space where awareness is currently low.